Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00247-023-05850-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Redefining glomerular hyperfiltration: pathophysiology, clinical implications, and novel perspectives.
Hypertens Res
January 2025
Department of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
Commentary: MR-DTI of the growth plate: redefining concepts and evaluating future perspectives.
Pediatr Radiol
December 2024
Karolinska University Hospital, Stockholm, Sweden.
Neurophysiological markers in myelodysplastic syndromes: Insights into peripheral neuropathy.
Br J Haematol
November 2024
Department of Neurology, Hannover Medical School, Hannover, Germany.
In their paper, Papantoniou et al. present relevant findings on the prevalence and characteristics of peripheral neuropathy in patients with myelodysplastic syndromes (MDS), underscoring the necessity for a more nuanced understanding of neurophysiological involvement in this complex haematological disorder. Their study not only reveals a higher frequency of neuropathy in MDS patients than previously reported but also illuminates specific neurophysiological patterns that may redefine clinical expectations and diagnostic practices in MDS-associated peripheral neuropathy.
View Article and Find Full Text PDFBeyond the fill: Navigating pharmacy's technological future in 2050.
J Am Pharm Assoc (2003)
November 2024
The pharmacy profession stands at a pivotal juncture as it faces unprecedented technological advancements that will rapidly reshape the healthcare landscape by 2050. This commentary explores the implications of technological advancements for pharmacy practice and how it may impact the workforce in the coming decades. The advent of digital health technologies (DHTs), artificial intelligence (AI), and automation is poised to transform patient engagement and care delivery.
View Article and Find Full Text PDFConsolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care.
Transl Lung Cancer Res
October 2024
Division of Oncology, Department of Medicine, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!